Azure Health Technology (AZT) Board Announcement  30/4/2020

The Board of Azure Health Technology (AZT) (“the Company”) is pleased to advise of the following developments following the withdrawal of the recent AZT Offerassociated with a requotation of the ASX ("Offer"). These developments follow AZT receiving over 700 subscription applications for shares under a prospectus offer associated with the Offer, from inside and outside of Australia, representing some $7.2mil at the time of the close of the Offer.

We would like to thank you all who have participated and supported the offer.

Subsequent to the withdrawal of the Application:

  • AZT has completed the acquisition of Invictus Biopharma Ltd. on 11 June 2020.
  • The merged company pools the resources and networks of both companies, including branding, distribution, technologies, patents and, research and development capabilities;
  • Based on the various patents owned and research work undertaken by the new AZT, it will become a research and innovation-focused company. Not only will it attract long term investors, it will also be eligible to apply for government grants and subsidies for its research activities;
  • The board and management team is composed of industry and scientific experts from China, Australia, US and New Zealand, including Dr. Glenn Tong (Melbourne), Dr. David Kingston (Sydney), Dr. Richard Pestell (US) and Dr. Ed Gane (New Zealand);
  • The merger of the two companies has attracted interest from a number of Australian companies. The Company is currently negotiating a technology and production partnership with another Australian listed entity. The details of the transaction remain confidential and the company will be making an announcement once the transaction is finalised.

The board members of AZT welcome and look forward to working with the Invictus Biopharma’s team. We hope that, by the joint force between the two companies, the new AZT can progress the development of its pipeline of drug candidates in the near future to benefit patients suffering from Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic SteatoHepatitis (NASH) and pancreatic cancer. The new AZT, as an Innovative Enterprise, will advance its financing and capital raising activities. The Company will become one of a few companies that can make a difference to the welfare of our society through health technologies

The board would like to thank you again for your ongoing support to AZT.